Article
ERK inhibition overcomes acquired resistance to MEK inhibitors.
Molecular cancer therapeutics - 1 May 2012
Hatzivassiliou Georgia, Liu Bonnie, O'Brien Carol, Spoerke Jill M, Hoeflich Klaus P, Haverty Peter M, Soriano Robert, Forrest William F, Heldens Sherry, Chen Huifen, Toy Karen, Ha Connie, Zhou Wei, Song Kyung, Friedman Lori S, Amler Lukas C, Hampton Garret M, Moffat John, Belvin Marcia, Lackner Mark R
Abstract excerpt
The RAS/RAF/MEK pathway is activated in more than 30% of human cancers, most commonly via mutation in the K-ras oncogene and also via mutations in BRAF. Several allosteric mitogen-activated protein/extracellular signal-regulated kinase (MEK) inhibitors, aimed at treating tumors with RAS/RAF pathway alterations, are in clinical development. However, acquired resistance to these inhibitors has been documented both...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.